Abstract:<h3>Background</h3> The dynamic changes of N<sup>6</sup>-methyladenosine controlled by m<sup>6</sup>A regulators are vital for cancer biology.<sup>1</sup> However, the role of m<sup>6</sup>A regulators in lung adenocarcinoma (LUAD) remains unclear. This study aimed to gain a deeper insight into the roles of m<sup>6</sup>A regulators in LUAD by bioinformatics. <h3>Methods</h3> 31 m<sup>6</sup>A regulators were retrieved from previous literature. The expression levels of the 31 regulators were investigated by TIMER2.0. The association between the 31 regulators and overall survival (OS) were explored via K-M plotter and Cox regression. Next, mutations status and copy number alterations of the 31 regulators were probed through cBioPortal. Moreover, the interaction between the 31 regulators were revealed via principal component analysis (PCA), protein-protein interaction (PPI), and Metascape enrichment by R programming, STRING 11.5, Cytoscape, and Metascape. Then, the immune microenvironment including immune score, specific immune cells infiltration, and expressions of immune-related gene families were probed via ESTIMATE, TIMER2.0, TIMER, and R programming. Next, LUAD samples were divided into 3 clusters based on the expression patterns of the 31 regulators by k-means method. The differences of OS, gene enrichment, immune microenvironment of the 3 clusters were compared by Log-rank test, GSVA, ESTIMATE, and CIBERSORTx. Moreover, a m<sup>6</sup>A Score Model was constructed using stepwise regression in this study. The predicting ability of the m<sup>6</sup>A Score Model was verified by GEO LUAD dataset and TCGA Pan- adenocarcinoma dataset. <h3>Results</h3> 22 out of 31 regulators showed differential expression levels between LUAD and normal lung (figure 1). 28 out of 31 regulators were linked with OS (figure 2). The frequency of mutation and copy number alterations were 26.6% and 29.1% respectively (figure 3). PCA revealed the 31 m<sup>6</sup>A regulators displayed almost completely distinct distribution patterns between LUAD and normal lung (figure 4). PPI and Metascape enrichment indicated the 31 m<sup>6</sup>A regulators displayed close interrelation (figure 5). Between high and low expression groups of 20, 20 and 29 regulators, tumor purity, immune score, immune cells infiltrations exhibited statistical difference (figure 6). Moreover, 3 clusters displayed distinct OS, gene enrichment, and immune microenvironment (figure 7). Notably, a m<sup>6</sup>A Score Model was built up upon 15 m<sup>6</sup>A regulators (figure 8). The model was associated with OS for LUAD and pan-adenocarcinoma (figure 9). Conclusions m<sup>6</sup>A regulators are associated with molecular features, immune microenvironment and prognosis in LUAD. m<sup>6</sup>A Score could be used as a reference to immunotherapy and a prognostic index for LUAD. <h3>Reference</h3> Nombela P, Miguel-López B, Blanco S. The role of m6A, m5C and ? RNA modifications in cancer: Novel therapeutic opportunities. <i>Mol Cancer</i> 2021;<b>20</b>:18.

Genomics and Prognosis Analysis of N6-Methyladenosine Regulators in Lung Adenocarcinoma

A Prognostic Model of M6a-Related Lipid Metabolism-Associated Genes in Pancreatic Adenocarcinoma

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Head and Neck Squamous Cell Carcinoma

A Five-M6a Regulatory Gene Signature is a Prognostic Biomarker in Lung Adenocarcinoma Patients

Molecular characterization, biological function, tumor microenvironment association and clinical significance of m<SUP>6</SUP>A regulators in lung adenocarcinoma

Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System

N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma

A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma

1424 m<sup>6</sup>A regulators related to molecular feature, immune microenvironment and prognosis in lung adenocarcinoma

Comprehensive Analysis Revealed the Potential Implications of m6A Regulators in Lung Adenocarcinoma

Analysis of m6A modulator-mediated methylation modification patterns and the tumor microenvironment in lung adenocarcinoma

Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma

M7g-Related Mirna Signature for Prediction of Prognosis in Lung Adenocarcinoma

N6-methyladenosine Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients with Colorectal Cancer

Identification of the Signature Associated With m6A RNA Methylation Regulators and m6A-Related Genes and Construction of the Risk Score for Prognostication in Early-Stage Lung Adenocarcinoma

N6-Methyladenosine-Regulated mRNAs: Potential Prognostic Biomarkers for Patients With Lung Adenocarcinoma

Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma

N6-methyladenosine (m6A) regulator expression pattern correlates with the immune landscape in lung adenocarcinoma.

m6A RNA Methylation Regulators Act as Potential Prognostic Biomarkers in Lung Adenocarcinoma

Characterization of m6A RNA Methylation Regulators Predicts Survival and Immunotherapy in Lung Adenocarcinoma

Link between m6A modification and infiltration characterization of tumor microenvironment in lung adenocarcinoma